PFE Stock Price - Pfizer Inc - (PFE)
- Prev. Close: 34.59
- Open: 34.43
- Daily Range: 34.29 - 34.66
PFE NEWS FROM BIDNESS ETC
Pfizer, Inc., Novartis AG Criticize CDC’s Recommendation For Meningitis B...
A CDC advisory committee has recommended meningitis B vaccines for people at high risk of ages 10-25; however, the pharma giants are not too happy wit...
NICE Okays Pfizer Inc. Inlyta, Rejects Dendreon Corporation Provenge; Bad N...
Dendreon’s prostate cancer drug Provenge failed NICE’s cost-benefit analysis, landing a blow to Valeant, who recently acquired the bankrupt biotec...
Insider Selling: General Motors Company (GM), Pfizer Inc. (PFE), Procter &a...
Bidness Etc takes a look at recent insider selling transactions that occurred in General Motors, Pfizer, Proctor & Gamble, and T-Mobile US
- Hospira, Inc. Profits Exceed Estimates On Strong Sales Of Injectables
- Pfizer Inc. (PFE) Strikes A $5 Billion Accelerated Share Repurchase Deal Wi...
- Hospira, Inc. Acquisition Calls For A Price Target Raise On Pfizer (PFE) St...
- Here’s Why BMO Capital Markets Sees Upside In Pfizer Inc. Stock
- Pfizer Inc. GEP Unit To Become Largest Biosimilar And Generic Drugs Develop...
- Pfizer Inc. Is Not Done With Acquisition Deals Yet
- Hospira, Inc. Stock Jumps After Pfizer Inc. (PFE) Agrees To Acquisition
- Pfizer Inc. To Acquire Hospira (HSP) For $17 Billion
- Pfizer Inc Breast Cancer Drug Wins FDA Approval
More News From Bidness
Pfizer Inc. (PFE) Terminates $70 Million Deal With Repl... PUBLISHED: Feb 1, 2015 at 9:48 am ESTPfizer Earnings Forecast Hit By Loss Of Patents And Str... PUBLISHED: Jan 27, 2015 at 2:40 pm ESTPfizer Inc. (PFE) Will Further Reduce Prevenar 13 Price... PUBLISHED: Jan 27, 2015 at 8:13 am ESTPfizer Inc. (PFE) Q4 Earnings Preview: High Organic Gro... PUBLISHED: Jan 27, 2015 at 6:32 am EST
Pfizer Inc. (PFE) Looks For Other Acquisition Targets After Teva Pharmaceutical (TEVA) Rejection PUBLISHED: Jan 26, 2015 at 6:29 am EST
Here’s What Pfizer Inc. Could Do With Its $33 Billion Cash Pile PUBLISHED: Jan 26, 2015 at 6:29 am EST
Pfizer is expected to shed some light on how it plans to best use its huge cash pile this week, as it announces results for the fourth quarter and full fiscal 2014READ MORE
Pfizer Takes On With Amgen, Sanofi In PCSK9 Inhibitor Race PUBLISHED: Jan 21, 2015 at 9:53 am EST
Pfizer emphasizes on different dosages and primary prevention to differentiate its drug from rivalsREAD MORE
Pfizer To Enhance Focus On Cancer Immunotherapy Drugs PUBLISHED: Jan 15, 2015 at 11:16 am EST
Pfizer plans to focus its R&D efforts on developing immunotherapy drugs for cancers other than melanoma in an attempt to lead the most lucrative segment of the industryREAD MORE
Pfizer Inc Continues Talks With FDA Regarding Breast Cancer Drug PUBLISHED: Jan 9, 2015 at 9:44 am EST
Pfizer stock rose more than 2% yesterday on the announcement that the company’s experimental breast cancer treatment might be approved in AprilREAD MORE
Pfizer Inc And Actavis plc Likely To Make Acquisition-Related Moves In 2015 PUBLISHED: Jan 8, 2015 at 7:42 am EST
2014 turned out to be the most active year in decades for the health-care industry in terms of mergers and acquisitions, and 2015 is expected to be no different, as companies look to boost their pipeline and outdo rivalsREAD MORE
Pfizer (PFE) Reports Positive Phase III Results For Nerve-Pain Drug PUBLISHED: Dec 19, 2014 at 7:10 am EST
Pfizer announced its drug Lyrica showed statistically significant results in treating postherpetic neuralgia, or nerve pain, compared to a placeboREAD MORE